Positive results for Roche’s experimental eye drug should bolster its position in the multibillion-dollar-a-year market for vision loss treatments, as it looks to branch out beyond its core cancer expertise. After scrapping drugs to treat diabetes and boost levels of “good” high-density cholesterol, the world’s largest maker of cancer drugs is hoping to prove it has a stronger hand when it comes to developing treatments for the eyes. The company has already chalked up one success with Lucentis, a treatment for wet age-related macula degeneration (AMD), which had sales of $1.5 billion in the United States last year.
Help employers find you! Check out all the jobs and post your resume.
